August 13, 2019

Boehringer Ingelheim opens animal health facility in China


Boehringer Ingelheim has announced the opening of the Boehringer Ingelheim Health Management Centre (HMC) in China on August 12.

The HMC is the first of its kind that is established by a multinational animal health company in the country, Boehringer said. Designed for world leading veterinary reference laboratories, the centre integrates animal disease and health diagnostics as well as monitoring tools to maintain and enhance animal health.

Located in Shanghai's Zhangjiang Hi-Tech Park, the HMC has an investment of nearly €3 million (US$3.4 million) in its first phase. The facility - which has a projected staff of 25 people - is described as a full service reference laboratory with all diagnostic disciplines to provide comprehensive diagnosis for animal diseases.

In addition, the veterinary reference laboratory of the HMC, contains a serology lab, a molecular biology lab and a bacteriology lab, and is capable of detecting more than 10 animal pathogens. It comprises state-of-the-art design, functionality, safety, and is eco-friendly. Several high-tech components also allow for rapid detection with maximum quality control.

The centre aims to build Boehringer Ingelheim customers' own diagnostic capabilities and capacity, functioning both as a reference laboratory and training centre which will provide comprehensive training in laboratory management, quality control, diagnostic platforms and other activities, the company said. It is accredited with the China National Accreditation Service for Conformity Assessment (CNAS).

Dr. Stephan Lange, head of animal jealth for China's mainland, Hong Kong and Taiwan at Boehringer Ingelheim, said: "The opening of the HMC is another milestone for Boehringer Ingelheim in China. The HMC forms an integral part of living our "In China, for China" commitment. It further strengthens our ability to provide services along the full value chain for Chinese customers and highlights our commitment to continue to invest in China. We hope to best manage animal health and maximise productivity and profitability for our customers, as well as contribute to the improvement of animal and human health."

- Boehringer Ingelheim